Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.

MLA

Asselah, Tarik, et al. “Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, vol. 16, no. 3, Mar. 2018, pp. 417–26. EBSCOhost, https://doi.org/10.1016/j.cgh.2017.09.027.

APA

Asselah, T., Kowdley, K. V., Zadeikis, N., Wang, S., Hassanein, T., Horsmans, Y., Colombo, M., Calinas, F., Aguilar, H., de Ledinghen, V., Mantry, P. S., Hezode, C., Marinho, R. T., Agarwal, K., Nevens, F., Elkhashab, M., Kort, J., Liu, R., Ng, T. I., … Mensa, F. J. (2018). Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, 16(3), 417–426. https://doi.org/10.1016/j.cgh.2017.09.027

Chicago

Asselah, Tarik, Kris V Kowdley, Neddie Zadeikis, Stanley Wang, Tarek Hassanein, Yves Horsmans, Massimo Colombo, et al. 2018. “Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 16 (3): 417–26. doi:10.1016/j.cgh.2017.09.027.